Insulin derivatives having an extremely delayed time-action profile

US9644017B2 · kind B2 · utility

Assignee

• Sanofi-Aventis Deutschland GMBH · DE

Inventors

• Paul Habermann · Solms, DE
• Gerhard Seipke · Hofheim, DE
• Roland Kurrle · Frankfurt am Main, DE
• Gunter Muller · Frankfurt am Main, DE
• Mark Sommerfeld · Frankfurt am Main, DE
• Norbert Tennagels · Siegburg, DE
• Georg Tschank · Frankfurt am Main, DE
• Ulrich Werner · Frankfurt am Main, DE

Key dates

• Filing date: Jun 22, 2010
• Grant date: May 9, 2017
• Expiry date: Jan 10, 2032

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61K38/00
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The invention relates to novel insulin analogs having a basal time-action profile, which are characterized by the following features: a) the B chain end consists of an amidated basic amino acid residue such as lysine or arginine amide; b) the N-terminal amino acid residue of the insulin A chain is a lysine or arginine radical; c) the amino acid position A8 is occupied by a histidine radical; d) the amino acid position A21 is occupied by a glycine radical; and e) one or more substitutions and/or additions of negatively charged amino acid residues are carried out in the positions A5, A15, A18, B-1, B0, B1, B2, B3 and B4.